Shenyang Xingqi Pharmaceutical Co Ltd Total Assets
Shenyang Xingqi Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Shenyang Xingqi Pharmaceutical Co Ltd (300573) holds total assets worth CN¥2.42 Billion CNY (≈ $354.04 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 300573 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Shenyang Xingqi Pharmaceutical Co Ltd (2011–2024)
Total assets of Shenyang Xingqi Pharmaceutical Co Ltd from 2011 to 2024. This chart illustrates how Shenyang Xingqi Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See current stock price of Shenyang Xingqi Pharmaceutical Co Ltd for real-time trading data and today's change.
Shenyang Xingqi Pharmaceutical Co Ltd - Asset Composition Analysis
Shenyang Xingqi Pharmaceutical Co Ltd Total Assets Breakdown (December 2024)
Shenyang Xingqi Pharmaceutical Co Ltd total assets breakdown as of December 2024. Shenyang Xingqi Pharmaceutical Co Ltd's total assets of CN¥2.42 Billion consist of 39.0% current assets and 61.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 17.4% |
| Accounts Receivable | CN¥281.30 Million | 13.2% |
| Inventory | CN¥153.60 Million | 7.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥194.18 Million | 9.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Shenyang Xingqi Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 300573 working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shenyang Xingqi Pharmaceutical Co Ltd's current assets represent 39.0% of total assets in 2024, a decrease from 68.3% in 2011.
- Cash Position: Cash and equivalents constituted 17.4% of total assets in 2024, down from 36.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, a decrease from 10.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 13.2% of total assets.
Shenyang Xingqi Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Shenyang Xingqi Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Autek China Inc
SHE:300595
|
China | CN¥6.40 Billion |
|
Pegavision
TW:6491
|
Taiwan | NT$16.17 Billion |
|
Crossject
PA:ALCJ
|
France | €30.43 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.39 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
Shenyang Xingqi Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.90 | 1.96 | 1.38 |
| Quick Ratio | 1.55 | 1.66 | 1.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥446.37 Million | CN¥464.41 Million | CN¥81.72 Million |
Shenyang Xingqi Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shenyang Xingqi Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.38 |
| Latest Market Cap to Assets Ratio | 0.61 |
| Asset Growth Rate (YoY) | 5.1% |
| Total Assets | CN¥2.13 Billion |
| Market Capitalization | $1.30 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shenyang Xingqi Pharmaceutical Co Ltd's assets below their book value (0.61x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Shenyang Xingqi Pharmaceutical Co Ltd's assets grew by 5.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Shenyang Xingqi Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total assets of Shenyang Xingqi Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.13 Billion ≈ $311.34 Million |
+5.13% |
| 2023-12-31 | CN¥2.02 Billion ≈ $296.15 Million |
+13.51% |
| 2022-12-31 | CN¥1.78 Billion ≈ $260.90 Million |
+5.70% |
| 2021-12-31 | CN¥1.69 Billion ≈ $246.84 Million |
+74.68% |
| 2020-12-31 | CN¥965.70 Million ≈ $141.31 Million |
+13.30% |
| 2019-12-31 | CN¥852.37 Million ≈ $124.73 Million |
+20.31% |
| 2018-12-31 | CN¥708.47 Million ≈ $103.67 Million |
+4.73% |
| 2017-12-31 | CN¥676.48 Million ≈ $98.99 Million |
-6.23% |
| 2016-12-31 | CN¥721.41 Million ≈ $105.57 Million |
+10.83% |
| 2015-12-31 | CN¥650.94 Million ≈ $95.25 Million |
-2.98% |
| 2014-12-31 | CN¥670.90 Million ≈ $98.17 Million |
+18.28% |
| 2013-12-31 | CN¥567.21 Million ≈ $83.00 Million |
+35.69% |
| 2012-12-31 | CN¥418.02 Million ≈ $61.17 Million |
+56.05% |
| 2011-12-31 | CN¥267.88 Million ≈ $39.20 Million |
-- |
About Shenyang Xingqi Pharmaceutical Co Ltd
Shenyang Xingqi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of ophthalmic medications in the People's Republic of China. The company provides myopia prevention and control medications, nutrition and corneal repair drugs, ophthalmic anti-inflammatory/anti-infective drugs, artificial tears and eye lubricants, ophthalmic non-steroidal anti-inflammatory drugs… Read more